Navigation Links
CoAxia(TM) Announces $11.5M Equity Financing From Existing Investors
Date:4/1/2008

New equity infusion continues funding CoAxia's studies of its NeuroFlo(TM)

Perfusion Augmentation Therapy for Ischemic Stroke

MINNEAPOLIS, April 1, 2008 /PRNewswire/ -- CoAxia(TM), Inc. of Maple Grove, MN, today announced the closing of an additional $11.5M financing from current investors to support the continuation of CoAxia's ongoing clinical trials. The investment is an extension of the previously announced C Round and will allow CoAxia to continue its SENTIS pivotal FDA trial of NeuroFlo Perfusion Augmentation Therapy in acute ischemic stroke, as well as other ongoing feasibility studies to evaluate use of the same technology in additional stroke populations.

Canaan Partners and Prism Venture Partners co-led the recent $11.5M financing, with Baird Venture Partners, Affinity Capital Management, Johnson and Johnson Development Corporation and SVB Capital Partners also participating as major investors.

Brent Ahrens, General Partner from Canaan Partners stated, "Speaking for my colleagues involved in the CoAxia investment, we are pleased with the progress made by the team at CoAxia, and believe that the NeuroFlo technology has the potential to be widely applied in ischemic stroke -- with major benefit to stroke patients."

Andrew M. Weiss, President and CEO commented, "We are grateful for the support from our current investors, who, with the conclusion of this C Round extension, have invested more than $30M in CoAxia and the NeuroFlo technology. Our objective for the coming 24 months is to finish enrollment in our SENTIS pivotal trial, demonstrate the feasibility of NeuroFlo in several large stroke patient populations, and begin positioning CoAxia for future commercialization."

Enrollment in CoAxia's ongoing SENTIS clinical trial has now passed 125 patients with participation from over 50 major stroke centers in North America and Europe. Analysis of interim safety data suggests that treatment with CoAxia's NeuroF
'/>"/>

SOURCE CoAxia, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
5. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
6. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
7. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
8. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
9. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
10. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
11. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/16/2009)... SALT LAKE CITY, Dec. 16 ... or the "Company"), a medical device company engaged ... breast ultrasound imaging system, announced today that Joe ... Board of Directors. ,, Board Chairman Ken ... to large medical devices companies, including GE OEC ...
(Date:12/16/2009)... Naurex Inc., a new clinical stage company developing ... based on its novel GFPA NMDA receptor modulators, ... I clinical trial of its lead compound GLYX-13 ... the study. GLYX-13, a glycine site functional ... receptor, is initially being developed as a therapy ...
(Date:12/16/2009)... ALTO, Calif., Dec. 16 The Boards ... Corporation are delighted to announce the merger of ... the field of RNAi (RNA interference). The ... have multiple RNAi discovery, development and delivery technologies, ... a broad portfolio of intellectual property. ,, ...
Breaking Medicine Technology:In Preparation for Commercialization of SVARA(TM), TechniScan Appoints Joe Pepper, PhD to Board of Directors 2In Preparation for Commercialization of SVARA(TM), TechniScan Appoints Joe Pepper, PhD to Board of Directors 3Naurex Inc. Initiates Phase I Clinical Trial of its Novel Mechanism NMDA Modulator GLYX-13 in Treatment-Resistant Depression 2Naurex Inc. Initiates Phase I Clinical Trial of its Novel Mechanism NMDA Modulator GLYX-13 in Treatment-Resistant Depression 3Silence Therapeutics to Merge with Intradigm Corp to Create Leading RNAi Therapeutics Company 2Silence Therapeutics to Merge with Intradigm Corp to Create Leading RNAi Therapeutics Company 3Silence Therapeutics to Merge with Intradigm Corp to Create Leading RNAi Therapeutics Company 4Silence Therapeutics to Merge with Intradigm Corp to Create Leading RNAi Therapeutics Company 5Silence Therapeutics to Merge with Intradigm Corp to Create Leading RNAi Therapeutics Company 6HMS Acquires IntegriGuard to Expand Program Integrity Capabilities 58521 1HMS Acquires IntegriGuard to Expand Program Integrity Capabilities 58521 2Patient Targeted Messaging for Emerging Multiple Sclerosis Agents Needs to Highlight Efficacy and Preservation of Quality of Life 5097 1Patient Targeted Messaging for Emerging Multiple Sclerosis Agents Needs to Highlight Efficacy and Preservation of Quality of Life 5097 2Patient Targeted Messaging for Emerging Multiple Sclerosis Agents Needs to Highlight Efficacy and Preservation of Quality of Life 5097 3Harris Corporation Demonstrates Secure Exchange of Public Health Information in Cloud Computing Environment 58517 1Harris Corporation Demonstrates Secure Exchange of Public Health Information in Cloud Computing Environment 58517 2Harris Corporation Demonstrates Secure Exchange of Public Health Information in Cloud Computing Environment 58517 3
... showed an improvement in median survival vs. ... parallel external controls -, ... today announced updated results from the Phase 2 study of,its investigational ... cytotoxic T lymphocyte (CTL) responses,and showed a positive survival trend in ...
... Nov. 1 In a move to improve,significantly ... leader in emergency medical information service, has joined,the ... and,support, to offer MedicAlert(R) + Safe Return(R). Currently, ... Alzheimer,s and almost 10 million,people caring for someone ...
Other Medicine Technology:IDM Pharma Announces IDM-2101 Updated Phase 2 Results Show Treatment Well Tolerated With Positive Survival Trend in Lung Cancer Patients 2IDM Pharma Announces IDM-2101 Updated Phase 2 Results Show Treatment Well Tolerated With Positive Survival Trend in Lung Cancer Patients 3IDM Pharma Announces IDM-2101 Updated Phase 2 Results Show Treatment Well Tolerated With Positive Survival Trend in Lung Cancer Patients 4MedicAlert Foundation Joins The Alzheimer's Association to Offer MedicAlert(R) + Alzheimer's Association Safe Return(R) - Live 24-Hour Emergency Response for Wandering and Medical Emergencies 2MedicAlert Foundation Joins The Alzheimer's Association to Offer MedicAlert(R) + Alzheimer's Association Safe Return(R) - Live 24-Hour Emergency Response for Wandering and Medical Emergencies 3
(Date:12/16/2009)... New Enterprise Associates, Inc. (NEA), a leading global ... its portfolio companies, Acclarent, Inc., has entered into ... Inc., a Johnson & Johnson company, in an ... estimated cash on hand at time of closing). ... and commercializing devices that address conditions affecting the ...
(Date:12/16/2009)... Blacks, other minorities might not gain full benefit from ... -- Human embryonic stem cell lines currently used for ... finds. , That could mean that non-whites will ... that research down the line, experts say. , Blacks ... most widely used stem cell lines studied showed any ...
(Date:12/16/2009)... WASHINGTON, Dec. 16 Losing has never felt ... knows maintaining his healthy new lifestyle means continuing to ... Drinking fat free milk is one healthy choice that ... a simple step everyone can take. Every glass of ... muscle, potassium to help maintain normal blood pressure, and ...
(Date:12/16/2009)... For wounded U.S. servicemen and women recovering at ... holidays can be a particularly difficult time. Wounded ... than ever on the healing power of connecting with ... got easier for Walter Reed patients as Verizon Wireless ... hundreds of minutes of holiday talk time for 2,500 ...
(Date:12/16/2009)... WASHINGTON, Dec. 16 As a result of ... a new peer reviewed cancer research program is included ... ,, This new cancer research program will research ... the breast, prostate, lung and ovarian cancer research programs ... Command. ,, The $15 million in funding ...
Breaking Medicine News(10 mins):Health News:NEA-Incubated Acclarent Acquired by Johnson & Johnson's Ethicon 2Health News:NEA-Incubated Acclarent Acquired by Johnson & Johnson's Ethicon 3Health News:Most Stem Cells Used in Research Come From Whites 2Health News:Verizon Wireless Donates $10,000 in Long-Distance Calling Cards to Soldiers at Walter Reed Hospital 2Health News:House Creates New Cancer Research Program 2Health News:House Creates New Cancer Research Program 3
... patients with chronic obstructive pulmonary disease (COPD) improves exercise ... unless they have resting hypoxemia, according to researchers in ... prescribed for those who do not meet criteria for ... of Medicine and Physical Therapy at West Park Healthcare ...
... pregnancy and breastfeeding may be putting their children at ... study funded by the Wellcome Trust and carried out ... that pregnant and breastfeeding women should not indulge in ... that they are "eating for two". , The study(1), ...
... is greater among kidney transplant patients and people with ... suggests the disease is associated with immune deficiency. ... South Wales in Sydney and colleagues compared the incidence ... with that of kidney transplant patients, who have suppressed ...
... measure apolipoprotein (apo) B: apo A-I ratio is not ... traditional lipid ratios that include total cholesterol and HDL-C, ... of JAMA. , Current risk-prediction instruments and guidelines for ... low-density lipoprotein cholesterol (LDL-C), total cholesterol, or both for ...
... can improve their understanding of the potential increased risk ... recent study conducted by researchers from The Childrens Hospital ... in New Haven, CT. , Like many radiology departments ... radiation exposure to children caused by increased usage of ...
Frederic Geissmann and colleagues find that Langerhans cell accumulation in Langerhans cell histiocytosis results from survival rather than uncontrolled proliferation, and is associated with the expan...
Other Medicine News:Health News:Ambulatory oxygen rarely a benefit in COPD patients without resting hypoxemia 2Health News:Eating junk food whilst pregnant and breastfeeding may lead to obese offspring 2Health News:Use of certain lipid measures not more effective in predicting coronary heart disease 2Health News:Informational handout key to giving parents a better understanding of CT radiation risks 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: